Cappella, the Galway based medical device company that is developing new treatments for Complex Coronary Artery Disease announced today that it has secured USD17.3m in new funding.The funds will allow the company to expand its pipeline, supplement ongoing clinical studies and support the European launch its Sideguard Sidebranch stent (a very small, very smart stent), in a market that was worth USD1 billion last year.
